Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
4 trials since 2013, 1 ongoing, by the sponsor of the products; see every authorized trial
Brigatinib in patients with anaplastic lymphoma kinase-positive (ALK+), advanced non¿small-cell lung cancer (NSCLC)…Aug 30, 2018 · Closed · Brigatinib
A phase 3 multicenter open-label study of brigatinib (AP26113) versus crizotinib in patients with ALK-positive advanced…May 31, 2016 · Closed · Brigatinib (AP26113)
A randomized, open-label study of ponatinib versus nilotinib in patients with chronic myeloid leukemia in chronic phase…Sep 3, 2015 · Closed · Ponatinib
A randomized phase 2 study of AP26113 in patients with ALK-positive, non-small cell lung cancer (NSCLC) previously…May 30, 2014 · Ongoing · Brigatinib (AP26113)
Orphan designations (FDA)
One designation since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
PonatinibTreatment of gastrointestinal stromal tumors (GIST). · Mar 12, 2015
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.